scispace - formally typeset
R

Richard E. Champlin

Researcher at University of Texas MD Anderson Cancer Center

Publications -  1500
Citations -  73470

Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.

Papers
More filters
Journal ArticleDOI

Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis.

Paolo Anderlini, +4 more
- 01 Jul 1996 - 
TL;DR: A reduction in the total leucocyte count below baseline levels was noted, accounted for by a decrease in the absolute neutrophil (ANC) and lymphocyte counts, and neutropenia occurred in two of the donors.
Journal ArticleDOI

Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation.

Bita Esmaeli, +5 more
- 01 Mar 2001 - 
TL;DR: A 40-year-old woman with a history of precursor T-cell acute lymphoblastic leukemia who developed an orbital mass associated with diffuse infiltration of the paranasal sinuses whose clinical and radiologic findings suggested an orbital abscess is described.
Journal ArticleDOI

Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer

Drew J. Winston, +13 more
- 01 Aug 1988 - 
TL;DR: It is suggested that interferon modifies the severity of herpes zoster in immunosuppressed patients with cancer but is associated with frequent side effects.
Journal ArticleDOI

Umbilical cord blood-derived cells for tissue repair

Martin Korbling, +4 more
- 01 Jan 2005 - 
TL;DR: Using the xenogeneic human into NOD/SCID mouse stem cell transplant model preliminary data suggest UCB-derived tissue-specific cells generated in liver, pancreas, CNS and endothelium.
Journal ArticleDOI

Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia

Partow Kebriaei, +11 more
- 01 Aug 2006 - 
TL;DR: The addition of rituximab to the standard Cy/TBI transplant conditioning regimen in ALL was safe and well tolerated, and there was a suggestion of decreased incidence of acute GVHD when compared to historically reported GV HD rates for this group of patients.